Aziyo Biologics Overview

  • Founded
  • 2015
Founded
  • Status
  • Public
  • Employees
  • 150
Employees
  • Stock Symbol
  • AZYO
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $10.98
  • (As of Friday Closing)

Aziyo Biologics General Information

Description

Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

Contact Information

Website
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
NAS
Primary Office
  • 12510 Prosperity Drive
  • Suite 370
  • Silver Spring, MD 20904
  • United States
+1 (240) 000-0000

Aziyo Biologics Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Aziyo Biologics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$10.98 $10.82 $10.64 - $18.00 $112M 10.2M 171K -$2.45

Aziyo Biologics Financials Summary

In Thousands,
USD
TTM 30-Jun-2020 FY 2020 30-Jun-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
Revenue 42,000 42,000 42,901 39,038
EBITDA (2,672) (2,202)
Net Income (11,939) (11,566)
Total Assets 44,772 47,741
Total Debt 25,531 19,457
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Aziyo Biologics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Aziyo Biologics‘s full profile, request access.

Request a free trial

Aziyo Biologics Executive Team (8)

Name Title Board Seat Contact Info
Ronald Lloyd Chief Executive Officer & Board Member
Matthew Ferguson Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Tom Englese Chief Commercial Officer
Jeffrey Hamet Vice President, Finance
Jerome Riebman MD Chief Medical Officer
You’re viewing 5 of 8 executive team members. Get the full list »

Aziyo Biologics Board Members (7)

Name Representing Role Since
000000 00000 Aziyo Biologics Board Member 000 0000
0000000 00000 00.0 Tissue Banks International Board Member 000 0000
00000 00000 Self Chairman & Board Member 000 0000
0000000 0000 HighCape Capital Board Member 000 0000
00000000 000000 Aziyo Biologics Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Aziyo Biologics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aziyo Biologics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Aziyo Biologics‘s full profile, request access.

Request a free trial

Aziyo Biologics Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 00000000 31-May-2017 0000000000 Surgical Devices 0000 000000000000 00.0
To view Aziyo Biologics’s complete investments history, request access »

Aziyo Biologics Subsidiaries (1)

Company Name Industry Location Founded
000000000 00000000 Surgical Devices Roswell, GA 0000
To view Aziyo Biologics’s complete subsidiaries history, request access »